No Data
No Data
Express News | Kyodo Pharmaceutical: The subsidiary Kyodo Steroid Research received a “Laboratory Accreditation Certificate from CNAS
Kyodo Pharmaceutical (300966): Q1 performance is in line with market expectations, product price increases, and gross profit margin increases
On the evening of April 25, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 566 million yuan (YoY -6.31%) and net profit of 23 million yuan (YoY-4)
Kyodo Pharmaceutical (300966.SZ): Net profit of 3,5473 million yuan in the first quarter decreased by 11.86% year on year
On April 25, Ge Longhui (300966.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 122 million yuan, up 2.35% year on year; net profit attributable to shareholders of listed companies was 3.5473 million yuan, down 11.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.4646 million yuan, up 2,911.68% year on year; basic earnings per share were 0.03 yuan.
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Pacific released a research report on April 14 stating that Kyodo Pharmaceutical (300966.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) being deeply involved in the steroidal drug field for nearly 20 years, layin
Pacific released a research report on April 14 stating that Kyodo Pharmaceutical (300966.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) being deeply involved in the steroidal drug field for nearly 20 years, laying out the entire industry chain from starting materials to APIs; 2) new process innovation is expected to drive rapid growth in the BA market; 3) steroidal drug intermediates are in the industry integration stage, and the company's product market share is expected to increase; 4) vertical expansion+horizontal expansion will open up the company's growth ceiling; 5) production capacity is about to be launched on a large scale to help revenue grow rapidly. (Mainichi Keizai Shimbun)
Kyodo Pharmaceutical (300966): Focus on expanding products in the field of steroidal drugs downstream to open up room for growth
Deeply involved in the field of steroidal drugs for nearly 20 years, laying out the entire industry chain from starting materials to APIs. The company was founded in 2006 and listed in 2021. In the early days of its establishment, the company mainly provided R&D, production and sales of steroidal drug intermediates, 201
No Data